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SUMMARY: In patients with ALS, conventional MR imaging is frequently noninformative, and its use
has been restricted to excluding other conditions that can mimic ALS. Conversely, the extensive
application of modern MR imagingbased techniques to the study of ALS has undoubtedly improved
our understanding of disease pathophysiology and is likely to have a role in the identification of
potential biomarkers of disease progression. This review summarizes how new MR imaging technol-
ogy is changing dramatically our understanding of the factors associated with ALS evolution and
highlights the reasons why it should be used more extensively in studies of disease progression,
including clinical trials.
ABBREVIATIONS: ALS amyotrophic lateral sclerosis; ALSFRS ALS Functional Rating Scale; Cho
 choline; Cr  creatine; CST  corticospinal tract; DTI  diffusion tensor imaging; FA  fractional
anisotropy; FLAIR  fluid-attenuated inversion recovery; fMRI  functional MR imaging; FTD 
frontotemporal dementia; FUS/TLS  fused in sarcoma/translocated in liposarcoma gene; GM 
gray matter; 1H-MR spectroscopy  proton MR spectroscopy; L  left; LMN  lower motor
neuron; MD  mean diffusivity; mIns  myo-inositol; MT  magnetization transfer; MTR  MT
ratio; NAA  N-acetylaspartate; ns  not significant; PD  proton density; R  right; SOD1 
superoxide dismutase 1; SPM  statistical parametric mapping; TDP-43  TAR DNA-binding
protein gene; UMN upper motor neuron; VBM voxel-based morphometry; WMwhite matter
ALS, also known as motor neuron disease, is a neurode-generative disorder characterized by a progressivemuscu-
lar paralysis reflecting degeneration of motor neurons in the
primary motor cortex, brain stem, and spinal cord. The
phenotypic expression of ALS is highly heterogeneous and de-
termined by 4 elements: 1) body region of onset, 2) relative
mix of UMN and LMN involvement, 3) rate of progression,
and 4) cognitive impairment.1 In approximately 5%–10% of
patients, the disease is inherited; 20% of these individuals
have amutationof theSOD1 gene; approximately 2%–5%,of the
TARDBP (TDP-43) gene; and 2%–4%, of the FUS/TLS gene.2
Most patientswithALS, however, have noobvious family history
andhave sporadicALS.2 To date, the only specificmarker of spo-
radic ALS is the presence of inclusions staining positively for
ubiquitin and TDP-43 in degenerating motor neurons.3
Despite technical advances in medicine in the last cen-
tury, the diagnosis of sporadic ALS relies on the interpreta-
tion of clinical symptoms and signs (ie, signs suggestive of
combined UMN and LMN degeneration, together with dis-
ease progression compatible with a neurodegenerative dis-
order). Paraclinical and laboratory tests are used only to ex-
clude “ALS-mimic” syndromes.4,5 In ALS, the absence of a
disease marker for UMN and LMN involvement has 2 main
negative consequences. First, the delay from onset of the dis-
ease to diagnosis of ALS can vary between 13 and 18 months6,7;
and the diagnostic delay may even be greater in patients who
present with isolated LMN signs.8 Such a delay precludes
early initiation of neuroprotective treatments.9 Second, the phe-
notypic heterogeneity of the disease is an important confounding
factor in clinical trials because it results in a limited inclusion of
patients (which requires the fulfillment of the revised El Escorial
criteria10) and in a highly variable treatment response.
Several neuroimagingmodalities have beenusedwith vary-
ing success either to aid the clinical process of establishing a
diagnosis of sporadic ALS or tomonitor disease progression.11
Conventional MR imaging of the brain and spinal cord has an
important role in the differential diagnosis.12 1H-MR spec-
troscopy and DTI hold promise for detecting and quantifying
subclinical UMN damage.11 The use of fMRI has provided
evidence for cortical reorganization in patients with ALS and
has contributed to achieving a more complete picture of the
ALS-related extramotor involvement.13 This review summa-
rizes the main results obtained from the application of con-
ventional and nonconventional MR imaging in patients with
ALS and highlights many areas for which more research is
warranted.
Conventional MR Imaging Findings
Routine anatomic imaging of the brain and/or the spinal
cord is helpful in ruling out diseases that mimic ALS with
varying degrees of UMN and LMN signs.5 The revised criteria
of the World Federation of Neurology Research Group on
Motor Neuron Diseases10 state that conventional MR imag-
ing studies are not required in those cases that have a clin-
ically definite disease with a bulbar or a pseudobulbar on-
set. On the other hand, in patients with clinically probable
or possibleALS,MR imaging can be useful in excluding several
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ALS-mimic syndromes, including cerebral lesions (eg, mul-
tiple sclerosis and cerebrovascular disease), skull base le-
sions, cervical spondylotic myelopathy, other myelopathy
(eg, foramen magnum lesions, intrinsic and extrinsic tumors,
and syringomyelia), conus lesions, and thoracolumbar sacral
radiculopathy.12
In patients with ALS, signal-intensity changes on conven-
tionalMR imaging (ie, T2-weighted, PD-weighted, and FLAIR
sequences) can be observed along the CST.14-23 Typically, CST
changes, which are best followed on coronal scans, appear as
areas of bilateral increased signal intensity from the centrum
semiovale to the brain stem. However, the frequency of CST
hyperintensities in patients with ALS varies significantly in the
different studies (ranging from15% to 76%), and it is not clear
yet which may be the most sensitive MR image to detect them
(Fig 1AD). The combined application of T2-weighted, PD-
weighted, and FLAIR images has recently reached a sensitivity
of approximately 62%.24 In addition, CST signal-intensity
changes do not correlate with clinical scores.17 More remark-
ably, CST hyperintensities have also been described in healthy
subjects,20 and in patients with other conditions, such as
Krabbe disease,25 X-linked Charcot-Marie Tooth neuropa-
thies,26 and adrenomyeloneuropathy.27
In patients with ALS, a characteristic low signal intensity
(hypointense rim) of the precentral cortex on T2-weighted
images can be observed (Fig 1E).16,18,19,21,22,28However, such a
change is neither sensitive nor specific to the pathology of ALS.
Symmetric T2 signal-intensity changes in the anterior tem-
poral subcortical WM have been described in patients with
ALS and dementia (Fig 1F).29,30 Pathologically, such hyperin-
tensities correspond to loss of myelin,30 WM degeneration,29
and gliosis.29
Significant lower whole brain volume has been found in
patients with ALS relative to healthy controls.31-33 Global
brain atrophy is, however, relatively mild.
Consistent with pathologic data, T2 and T1 hyperintensi-
ties of the anterolateral columns of the cervical cord have been
observed in patients with ALS.21,22,34 Such hyperintensities are
likely to have higher specificity than signal-intensity changes
on brain MR images.21,34 T1 hyperintensity of the anterolat-
eral cervical cord has been associated with a younger age and a
rapid disease progression.22
Fig 1. Conventional MR imaging findings in patients with ALS. AD, Hyperintensity at the subcortical precentral gyrus (A and B ) and the centrum semiovale (C and D) on FLAIR (arrows,
A and C) and T2-weighted (arrows, B and D) images of a 66-year-old patient with ALS. Modified with permission from Hecht et al.17 E and F, T2-weighted images obtained from a 58-year-old
patient with ALS with dementia show hypointensity along the precentral cortices (arrowheads, E ) and symmetric hyperintensity in the anterior temporal subcortical WM (arrows, F ). A
and D reprinted with permission from the Journal of the Neurological Sciences (2001;186:37–44). Copyright 2001, Elsevier Ltd.
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Nonconventional MR Imaging Assessment of the
Motor System
Regional Atrophy
Despite the consistent finding of cortical motor involvement
in pathologic studies of ALS,35 in vivoMR imaging studies did
not reach firm conclusions regarding the presence of motor/
premotor cortical atrophy because this was reported by some
authors (Fig 2),31,36-42 but not by others.32,43-45
Using VBM to assess the regional distribution of WM loss,
researchers have found atrophy of the CST in patients with
ALS,31,44 which was more severe in patients with a bulbar on-
set.44 Patients with ALS showed atrophy of the cervical cord
relative to controls,46 which significantly worsened during a
9-month follow-up.47
1H-MR Spectroscopy
In patients with ALS, 1H-MR spectroscopy studies demon-
strated a decrease in NAA concentrations48-50 and ratios of
NAA over Cr,50-54 Cho,51,55 and Cr  Cho54 in the motor
cortex. The physiologic role of NAA in the central nervous
system remains unclear. However, because NAA appears to
be present only in neurons of the adult human brain and in
their processes, the content of NAA is used as a biochemical
marker of neuronal integrity.56 These findings have been re-
cently confirmed at 3T.57-59 However, the diagnostic value
of 1H-MR spectroscopy is poor because of the considerable
overlap of the metrics of patients with those of healthy
controls.
Patients with ALS showed decreased NAA/Cr and NAA/
Cho ratios along the CST. Although the regional analysis of
these data showed more pronounced 1H-MR spectroscopy
changes in the precentral gyrus and corona radiata,60 NAA
reduction in the brain stem has also been reported.61
Cross-sectional studies have shown amoderate correlation
between NAA concentration (and its ratios) in the motor cor-
tex and clinical manifestations of ALS (ie, disease severi-
ty,50,59,62,63 extent of UMN signs,64 and maximum finger tap-
ping rate54). Patients with bulbar onset have the most severe
pattern of motor cortex 1H-MR spectroscopy changes com-
pared with those with a limb onset.
In addition to neuronal damage, increased glial cell activ-
ity, reflected by raised levels ofmIns, has been demonstrated in
the motor cortex of patients with ALS.51,65 Increased mIns
levels are associated with motor cortex hypointensity on T2-
weighted images.65 In a 3T 1H-MR spectroscopy study of pa-
tients with ALS,57 the NAA/mIns ratio provided better sensi-
tivity and specificity for detecting disease than the individual
metabolites and was the strongest correlation with disease
severity.
DTI
Using either region of interestbased approaches or tractog-
raphy, DTI studies of patients with ALS reported consistently
decreased FA and increased MD values along the CST (Fig
3).66-75 Loss of pyramidal motor neurons in the primary mo-
tor cortex and axonal degeneration of the CST, together with
the proliferation of glial cells, extracellular matrix expansion,
and intraneuron abnormalities,76 may contribute to the ob-
served CSTDTI changes. Themost pronounced decreased FA
and increased MD have been shown in the posterior limb of
internal capsule.66-74
Decreased FA in patients with ALS was found to correlate
with disease severity,59,66,67,71 rate of disease progression,74
and clinical67,69 and electrophysiologic70 measures of UMN
involvement. Patients with a bulbar onset exhibited the most
marked FA decrease.67 In 2 studies, increased MD of the CST
has been associated with disease duration.66,67
Compared with controls, patients with ALS had signifi-
cantly lower FA of the cervical cord, which was strongly asso-
ciated with the ALSFRS scores (Fig 4).46 This finding indicates
Fig 2. Regional GM atrophy in patients with ALS compared with controls. A group comparison of 17 patients with ALS versus 17 healthy controls37 shows regional GM atrophy in the
precentral and postcentral gyri bilaterally, which extends from the primary motor cortex to the premotor, parietal, and frontal regions bilaterally (displayed at P .001, uncorrected; extended
threshold, 100 voxels). The color bar represents the t-score. The differences between groups are superimposed on a standard normalized T1-weighted image. Images are shown in neurologic
convention.
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the presence of distortion of cord tissue geometry in ALS and
agrees with pathologic data showing a pronounced cord de-
generation and a reduction of the number of LMNs in the
anterior horns of the cord GM in patients with ALS.77
MT Imaging
Using T1-weighted MT images, 1 study showed hyperintensi-
ties along the CST (consistent with CST degeneration) in 80%
of patients with ALS.78 T1-weighted MT imaging provided
Fig 4. A and B, Illustrative examples of MD (images on the left of each pair) and FA (images on the right of each pair) maps of the cervical cord obtained from a healthy volunteer (A )
and a patient with ALS (B ). C, Scatterplot of the correlation between the cervical cord FA and the ALSFRS in 28 patients with ALS. Reprinted with permission from the Journal of Neurology,
Neurosurgery & Psychiatry (2007;78:480–84). Copyright 2007, BMJ Publishing Group Ltd.
Fig 3. A, A representative example of DTI tractography of the CST. B, Graphs of mean FA in the right and left CSTs of 28 patients with ALS (green) and 26 healthy controls (blue). Data
are presented for the entire CST (mean) and its pre- and postcentral portions. Mean values are shown with SDs (black lines). Significant differences in diffusion parameters between groups
are indicated by a red asterisk. Reprinted with permission from Neuroimage (2007;34:486–99). Copyright 2007, Elsevier Ltd.
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better sensitivity and specificity for detecting disease than
FLAIR images.78
Two MT imaging studies showed a reduction of the MTR
in the CST from 2.6%79 to 20%80 in patients with ALS com-
pared with controls. This finding was not confirmed by a re-
cent study.24 MT contrast is the result of cross relaxation and
chemical exchange between spins in the 2 pools of water pro-
tons: bound immobile protons associated with macromole-
cules (such asmyelin) and freemobile protons associated with
free water. MTR is a quantitative measurement of this phe-
nomenon, and it is correlated to the amount of bound protons
in the macromolecular matrix. Reduced MTR values have
been associated with axonal degeneration and myelin break-
down.81 A possible explanation for the negative results in the
study by Charil et al24 could be that gliosis secondary to axonal
loss might have led to a pseudonormalization of the MTR.
fMRI
During motor tasks, fMRI demonstrated an increased activa-
tion of the contralateral sensorimotor cortex and the sup-
plementary motor area (Fig 5A).82-85 Increased sensorimotor
activation was also reported in the hemisphere ipsilateral to
the movement.84 A spatial shift of recruitment to more ante-
rior regions of the premotor cortex during upper limb move-
ment was also observed in patients with ALS.82 In patients
with ALS, increased activation of the inferior parietal cortex
during a motor task has been reported. A relationship with
task difficulty84 or a compensatory role of thesemotor-related
areas82,85 has been suggested.
In ALS,motor executionwas also associatedwith increased
activations of areas involved in motor learning, such as the
basal ganglia and the cerebellum (Fig 5A).83,86 It is suggested
that an increase in movement-associated cortical activations
beyond the primarymotor cortex is associated with the degree
of UMN involvement.86
Nonconventional MR Imaging Assessment of the
Extramotor Regions
Regional Atrophy
The pattern of regional GM loss in patients with ALS extends
beyond the motor cortex to the frontotemporal and parietal
regions (Fig 2).31,32,36-38,40,41,44 Themost severe atrophy of the
frontal regions has been observed in patients with ALS and
FTD.38 In addition, patients with ALS with even subtle cogni-
tive and/or behavioral impairment (not meeting the criteria
for a diagnosis of FTD87) demonstratedGM loss in the frontal,
parietal, and limbic regions compared with those with no ev-
idence of cognitive deficits.88 These findings are consistent
with pathologic studies demonstrating ubiquitin-positive in-
traneuronal inclusions and neuronal loss extending beyond
the motor system in patients with ALS with or without cogni-
tive impairment.35
VBM studies in patients with ALS have provided evidence
for WM atrophy in extramotor areas, which include the cor-
pus callosum, the cerebellum, and the frontotemporal and
occipital areas.31,33,45 In 1 study of cognitively impaired non-
Fig 5. A, Brain regions showing a significant increased recruitment on fMRI scans from 10 patients with ALS relative to 10 healthy controls during right-handed movement (P  .05, small
volume correction). Modified with permission from Konrad et al.83 B and C, Areas of reduced fMRI activation in 28 nondemented patients with ALS relative to the control group during
letter fluency (B ) and confrontation naming (C ) tasks. A reprinted with permission from Experimental Brain Research (2006;172:361–69). Copyright 2006, Springer Science  Business
Media. B and C reprinted with permission from Brain (2004;127:1507–17). Copyright 2004, Oxford University Press.
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demented patients with ALS, a more severe frontotemporal
WM loss was associated with deficits on verbal fluency.45
Significant longitudinal cortical atrophy during a period of
1 year has been described in motor and prefrontal areas in
patients both with89 or without (Fig 6)90 clinical symptoms
typical of FTD.
1H-MR Spectroscopy
In patients with ALS, a decrease of NAA levels is not restricted
to the motor cortex and CST but also occurs in premotor
regions, the primary sensory cortex, and extramotor frontal
regions, with relative sparing of the parietal lobe.53,63 A corre-
lation was found between the decrease in the NAA/Cr ratio in
the frontal lobe and deficits of executive functions.63
DTI
In patientswithALS, FAdecrease has been found in the corpus
callosum36,75,91-93 and in several WM regions in the fron-
tal75,91,93 and temporal lobes.75,93 The topographic pattern of
MD changes in patients with ALS has been investigated by a
few studies, which showed increased MD in the corpus callo-
sum and in frontal and temporal WM regions compared with
controls.36,93
fMRI
Significantly reduced activation of the middle and inferior
frontal gyri, anterior cingulate cortex, and parietal and tem-
poral lobes was found in nondemented patients with ALS rel-
ative to controls during a letter fluency fMRI task (Fig 5B).94 A
confrontation naming fMRI task also revealed an impaired
activation of a prefrontal region (including Broca area) and
areas of the temporal, parietal, and occipital lobes (Fig 5C).94
This pattern of dysfunction correlated with cognitive deficits
on both word fluency and confrontation naming.94
Functional cortical changes have been observed in patients
with ALS without cognitive/behavioral impairment during
processing of socioemotional stimuli (ie, pictures of persons
in emotional situations).95 Compared with controls, patients
with ALS showed an increased activation of the right supra-
marginal gyrus.95
The Near Future of Neuroimaging of ALS
The Prognostic Value of MR Imaging
In ALS, death due to respiratory failure follows on average 3–5
years after onset. However, the survival of individual patients
with ALS is highly variable. A rapidly progressive course can
occur, but approximately 10% of patients survive for a decade
or more.96 Identifying predictors of progression and survival
in ALS is important for both management of patients in clin-
ical practice and design of new clinical trials. Older age at on-
set, bulbar site of onset, and a shorter time from symptom
onset to diagnosis are the most consistently reported clinical
predictors of shorter survival. A further contribution may
come from MR imaging by the identification of disease
changes earlier in the course of the disease. In one 1H-MR
spectroscopy study, a reduced short-term survival has been
associated with a lower NAA/Cho ratio.57
MR Imaging to Monitor Disease Evolution
Longitudinal neuroimaging studies are likely to contribute to
themonitoring of ALS progression. To date, only a few studies
Fig 6. Regions showing progression of GM atrophy during a 9-month period90 in 16 patients with ALS compared with 10 controls (red) and regions showing additional GM loss in clinically
rapidly progressing patients with ALS compared with both controls and nonrapidly progressing patients (green). A and B, Results are superimposed on the 3D rendering of the Montreal
Neurologic Institute standard brain and displayed at a threshold of P  .05, uncorrected. Color saturation depends on the position of the brain region in relation to the cortical surface
in the rendered brain (ie, motor, premotor, and prefrontal regions are more saturated; basal ganglia are less saturated). C and D, Plots showing the “size of effect” in the left premotor
and motor cortices for each group of subjects (healthy controls, patients with rapidly progressing ALS, and those with nonrapidly progressing ALS). The “size of the effect” was obtained
by plotting the estimates of the analysis of variance model parameters, which were of interest in the present analysis (3 subject groups). The bars represent the 90% confidence intervals.
Reprinted with permission from Amyotrophic Lateral Sclerosis (2009;10:168–74). Copyright 2009, Taylor and Francis.
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have attempted to assess quantitatively the dynamics of non-
conventional brain structural changes in patients with ALS,
and they provided conflicting results. Some studies have dem-
onstrated a significant decrease of the NAA level in the motor
cortex55,97-99 or the FA in the brain WM97 and cervical cord47
during 1 year. Changes of metabolite ratios and diffusivity
abnormalities were significantly correlated with progression
of disease severity.55,97 A serial 1H-MR spectroscopy study in-
dicated that a significant decrease of the NAA level also occurs
in brain extramotor regions after 9 months.99 However, in 1
prospective study of 30 patients with ALS, no significant
1H-MR spectroscopy and DTI changes were observed.50 Sim-
ilar negative findings have been found by others.47,100
The main limitation of longitudinal MR imaging studies
in ALS is the small sample sizes used. In addition, patients
recruited are typically advanced in their disease course,
which may imply that structural changes due to ALS pa-
thology had already occurred and stabilized at the time of
MR imaging, with only small changes occurring thereafter.
Finally, longitudinal MR imaging follow-up of patients
with ALS is limited by the declining ability of the patients to
tolerate the relatively long scanning time needed to obtain
meaningful quantitative MR imaging data. Future investi-
gations should involve larger groups of subjects, possibly
early in the course of the disease.
Despite many clinical trials and various advances in the
understanding of ALS, there has been little success in the
search for disease-modifying or neuroprotective agents. At
present, riluzole is the only approved drug that has been
shown to have amodest effect on prolonging life expectancy in
patients with ALS.96 The assessment of treatment effects on
1H-MR spectroscopy measures in ALS is only preliminary. A
rapid increase of the NAA/Cr ratio in the motor cortex in
patients with ALS after only 1 day of riluzole treatment has
been reported.101,102 Conversely, no effect on cortical meta-
bolic function has been observed with gabapentin treat-
ment103 or brain-derived neurotrophic factor.104 The reliabil-
ity and reproducibility of measures of brain 1H-MR
spectroscopy also warrant further investigation. In addition,
the sensitivity and clinical relevance of 1H-MR spectroscopy
scans in detecting longitudinal ALS-related changes need to be
established before this technique is used for monitoring treat-
ment efficacy in the context of multicenter clinical trials.
Iron-Dependent MR Imaging
Iron deposition is known to accumulate in the brain with nor-
mal aging, and recent studies have shown that iron is also
involved in brain damage in many chronic neurologic disor-
ders, such as Alzheimer disease, Parkinson disease, and mul-
tiple sclerosis.105 An abnormal iron deposition has been sup-
posed to be the substrate of T2 hypointense areas seen in the
cortex of patients with ALS.16,18,19,21,22,28 T2 and other se-
quences used at3T, such as T2*, T2, or T2-rho relaxometry;
magnetic field correlation imaging and susceptibility-
weighted imaging are likely to improve our ability to detect
iron deposition. As a consequence, iron-dependentMR imag-
ing may soon provide markers to monitor the progression of
brain damage in many neurologic diseases, including ALS.
fMRI
The difficulty of controlling task performance in patients with
ALS may be responsible for the variability of the results of
fMRI studies. The development of fMRI paradigms unbiased
by differences in task performance between patients with ALS
and controls,making the assessment ofmore disabled patients
feasible, should be considered. Motor imagery is known to
involve similar neural networks such as motor execution,
without being affected by confounding factors of effort and
strain. During a motor imagery task, patients with ALS
showed increased activation of the premotor and the primary
motor cortex.106 After 6 months, these differences persisted
with additional activations of the precentral gyrus and fronto-
parietal regions.106 In ALS, the resting-state fMRI studies
demonstrated not only changes in the premotor cortex but
also a reduced activation of the default mode network.107 An-
other aspect that should be considered is the combination of
measures of functional connectivity with those of structural
damage of specific WM tracts, which is likely to improve our
understanding of the relationship between morphologic and
functional abnormalities observed in this condition.
Conclusions
Findings compatible with ALS on conventional MR imaging
are not consistently found and are nonspecific. By demon-
strating evidence of occult UMNdegeneration in vivo, 1H-MR
spectroscopy and DTI may provide a faster and more defini-
tive diagnosis in suspected cases, leading to an earlier treat-
ment and enrollment in clinical trials. The extensive applica-
tion of modernMR imaging–based techniques to the study of
ALS has undoubtedly improved our understanding of disease
pathophysiology and may have a role in the identification of
potential biomarkers of disease progression. fMRI investigations
of the motor and cognitive networks in patients with ALS have
demonstrated an altered recruitment of regions normally de-
voted to the performance of a given task and/or the recruitment
of additional areas in comparison with healthy subjects.
Nevertheless, there are many remaining challenges. New
techniques need to be harnessed and integrated into clinical
research and practice. New acquisition schemes and analysis
procedures require standardization and optimization so that
they can be used in multiple settings, both in natural history
studies and treatment trials. From the data available, it is evi-
dent that combining different MR imaging modalities that
are sensitive to different aspects of ALS pathology (eg, motor
and extramotor) is a promising way to further increase our
understanding of themechanisms accounting for the accumu-
lation of irreversible disability in this condition.Moreover, the
emerging scenario from genetic studies indicates a consistent
overlap between the pathogenetic changes in most forms of
sporadic and familial ALS,108-110 thus suggesting that the ap-
plication of neuroimaging in familial patients with ALS may
allow identification of abnormalities that can hopefully be
translated to the assessment of sporadic ALS.
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